Content about Nitriles

December 3, 2013

Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.

NEWARK, N.J. — Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.

Developed alongside pharmacist, Robert Graci, Inergetics has created a unique formula to support healthy nerve function and specifically help diabetic patients who experience nerve-related symptoms in their extremities, which include tingling, pain, burning and loss of sensation, the company stated. 

September 13, 2012

The Food and Drug Administration has approved a generic psychiatric drug made by Lupin Pharmaceuticals, Lupin said Thursday.

BALTIMORE — The Food and Drug Administration has approved a generic psychiatric drug made by Lupin Pharmaceuticals, Lupin said Thursday.

The Indian drug maker announced the approval of escitalopram tablets in the 5-mg, 10-mg and 20-mg strengths, used for acute and maintenance treatment of major depressive disorder in adults and adolescents and for acute treatment of general anxiety disorder in adults.

March 27, 2012

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating HIV in children.

TITUSVILLE, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating HIV in children.

J&J's Janssen Therapeutics division announced Tuesday the FDA approval of Intelence (etravirine) in patients ages 6 years to younger than 18 years with HIV-1 who have taken other therapies but whose infection has become resistant to treatment. The drug already was approved for adults.

March 22, 2012

Teva Pharmaceutical Industries Ltd. announced on March 14 that it has commenced commercial launch of escitalopram oxalate tablets, the company’s generic version of Forest Laboratories’ depression and generalized anxiety disorder treatment Lexapro tablets.

Teva Pharmaceutical Industries Ltd. announced on March 14 that it has commenced commercial launch of escitalopram oxalate tablets, the company’s generic version of Forest Laboratories’ depression and generalized anxiety disorder treatment Lexapro tablets.

The branded product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data. As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

March 14, 2012

The Food and Drug Administration has approved the first generic version of an antidepressant made by Forest Labs, the agency said Wednesday.

SILVER SPRINGS, Md. — The Food and Drug Administration has approved the first generic version of an antidepressant made by Forest Labs, the agency said Wednesday.

The FDA announced the approval of a generic version of Lexapro (escitalopram) made by Teva Pharmaceutical Industries in the 5-mg, 10-mg and 20-mg strengths. The drug is used to treat depression and generalized anxiety disorder in adults.

February 29, 2012

Mylan has launched a generic drug for treating depression and anxiety, the company said Wednesday.

PITTSBURGH — Mylan has launched a generic drug for treating depression and anxiety, the company said Wednesday.

Mylan announced the launch of escitalopram tablets in the 5-mg, 10-mg and 20-mg strengths, the first generic version of Forest Labs' Lexapro. The drug is used for treating major depressive disorder and generalized anxiety disorder.

February 23, 2011

The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

PRINCETON, N.J., and WILMINGTON, Del. — The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

Bristol-Myers Squibb and AstraZeneca said the Food and Drug Administration approved the labeling update for Onglyza (saxagliptin), which now includes efficacy and safety information about the drug's effects on patients with renal impairment or end-stage renal disease.

January 11, 2011

The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

Merck announced the acceptance of its application for extended-release Janumet, which combines in a single pill the active ingredient sitagliptin with extended-release metformin, a drug commonly prescribed for Type 2 diabetes.

January 3, 2011

The Food and Drug Administration has approved an update to the label of a Johnson & Johnson drug for HIV, the company said Monday.

TITUSVILLE, N.J. — The Food and Drug Administration has approved an update to the label of a Johnson & Johnson drug for HIV, the company said Monday.

Tibotec Therapeutics, a subsidiary of J&J, said the FDA approved a 200-mg formulation of Intelence (etravirine) for treating HIV in patients who have taken previous treatments and whose virus has become resistant to antiretroviral drugs.

November 7, 2010

The Food and Drug Administration approved the first and only once-a-day metformin extended-release plus dipeptidyl...

October 27, 2010

Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug...

BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.

 

September 15, 2010

Drug maker Forest Pharmaceuticals will pay more than $300 million to the federal government as...

SILVER SPRING, Md. Drug maker Forest Pharmaceuticals will pay more than $300 million to the federal government as part of a plea agreement over alleged improper drug distribution and obstructing a Food and Drug Administration inspection.

August 10, 2010

The drug market for unipolar depression will get smaller over the next decade due to...

June 30, 2010

Anglo-Swedish drug maker AstraZeneca has created a savings card for users of one of its...

June 28, 2010

The Food and Drug Administration has approved two new generic versions of a drug for...

January 5, 2010

A research firm for pharmaceutical and healthcare issues projected sales of more than $1 billion...